What is Roth Capital’s Forecast for TENX Q1 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Analysts at Roth Capital issued their Q1 2025 earnings per share (EPS) estimates for Tenax Therapeutics in a research report issued on Wednesday, November 13th. Roth Capital analyst J. Aschoff anticipates that the specialty pharmaceutical company will post earnings per share of ($0.18) for the quarter. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($6.62) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.19) EPS and Q4 2025 earnings at ($0.20) EPS.

Several other brokerages have also recently commented on TENX. William Blair started coverage on shares of Tenax Therapeutics in a report on Monday, September 30th. They set an “outperform” rating on the stock. Leerink Partners assumed coverage on Tenax Therapeutics in a report on Thursday, October 24th. They issued an “outperform” rating and a $16.00 price objective for the company. StockNews.com started coverage on Tenax Therapeutics in a report on Thursday, September 26th. They set a “sell” rating on the stock. Guggenheim started coverage on Tenax Therapeutics in a research note on Monday, October 14th. They issued a “buy” rating and a $16.00 price target for the company. Finally, Leerink Partnrs upgraded shares of Tenax Therapeutics to a “strong-buy” rating in a research note on Thursday, October 24th. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Tenax Therapeutics Trading Down 1.4 %

Shares of Tenax Therapeutics stock opened at $4.87 on Friday. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $41.92. The company has a 50-day simple moving average of $3.99 and a two-hundred day simple moving average of $3.70.

Tenax Therapeutics (NASDAQ:TENX) last announced its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.99) by $0.16.

Hedge Funds Weigh In On Tenax Therapeutics

A number of institutional investors have recently modified their holdings of the business. Stonepine Capital Management LLC bought a new stake in shares of Tenax Therapeutics during the 3rd quarter worth $173,000. Vestal Point Capital LP acquired a new position in Tenax Therapeutics during the third quarter worth about $288,000. Finally, Sphera Funds Management LTD. bought a new position in shares of Tenax Therapeutics in the third quarter worth about $101,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.